Jupiter Acquisition CorporationJupiter Acquisition Corp • July 24th, 2020 • New York
This securities subscription agreement (this “Agreement”) is entered into as of the date set forth above by and between Mr. William Pate (the “Subscriber” or “you”) and Jupiter Acquisition Corporation, a Delaware corporation (the “Company”). Pursuant to the terms hereof, the Company accepts the offer the Subscriber has made to purchase 23,000 shares (“Founder Shares”) of Class B common stock, $0.0001 par value per share (the “Class B Common Stock” together with all other classes of Company (as defined below) common stock, the “Common Stock”), of the Company, up to 3,000 of which are subject to forfeiture by you if the underwriters of the proposed initial public offering (“IPO”) of the Company pursuant to the registration statement on Form S-1 expected to be filed by the Company in connection with the IPO (the “Registration Statement”) do not fully exercise their over-allotment option (the “Over-allotment Option”) as described below. The terms on which the Company is willing to sell the
Jupiter Acquisition CorporationSecurities Subscription Agreement • July 24th, 2020 • Jupiter Acquisition Corp • New York
This securities subscription agreement (this “Agreement”) is entered into as of the date set forth above by and between Mr. Robert A. Knox (the “Subscriber” or “you”) and Jupiter Acquisition Corporation, a Delaware corporation (the “Company”). Pursuant to the terms hereof, the Company accepts the offer the Subscriber has made to purchase 23,000 shares (“Founder Shares”) of Class B common stock, $0.0001 par value per share (the “Class B Common Stock” together with all other classes of Company (as defined below) common stock, the “Common Stock”), of the Company, up to 3,000 of which are subject to forfeiture by you if the underwriters of the proposed initial public offering (“IPO”) of the Company pursuant to the registration statement on Form S-1 expected to be filed by the Company in connection with the IPO (the “Registration Statement”) do not fully exercise their over-allotment option (the “Over-allotment Option”) as described below. The terms on which the Company is willing to sell t
